|Bid||24.51 x 1000|
|Ask||32.80 x 1200|
|Day's Range||28.00 - 28.78|
|52 Week Range||21.67 - 35.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.67|
Messemer's expertise in working with clients in banking and finance and grappling with rapid change will be useful in her board service.
The new leader discusses staffing and recruiting in the pricey Bay Area as well as his favorite rock bands and the benefits he gets from performing in his own improv troop, Butter Boost.
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 1:30 p.m. Pacific Time. A live audio webcast of the presentation will be available on the Investors section of Allogene’s website, www.allogene.com. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
The Cambridge biotech shattered records on Thursday night when it announced it had raised more than $604 million in an IPO, the largest ever in the sector.
The findings demonstrate the potential of ALLO-715 as a novel AlloCAR T therapy for multiple myeloma and other BCMA-positive malignancies. The data were presented today by Cesar Sommer, Ph.D., Principal Scientist at Allogene, in an oral session at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego. “Based on these promising preclinical data, we plan to submit an Investigational New Drug (IND) application for ALLO-715 and initiate a Phase 1 clinical trial in 2019 in relapsed or refractory multiple myeloma,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences in November 2018. A live audio webcast of each event will be available on the Investors section of Allogene’s website, www.allogene.com. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
SOUTH SAN FRANCISCO, Calif.-- -- Data Provide Insights in Preparation for Investigational New Drug Submissions Planned in 2019 for ALLO-501 in Non-Hodgkin Lymphoma and ALLO-715 in Multiple Myeloma Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced that it will present data supporting its allogeneic ...
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.
Details the CEO buys this past week from the following companies: Allogene Therapeutics, Conagra Brands, Texas Capital Bancshares, Fastenal and CymaBay Therapeutics
President and CEO of Allogene Therapeutics Inc (NASDAQ:ALLO) David D Chang bought 40,000 shares of ALLO on 10/15/2018 at an average price of $18 a share.
Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a ...
Allogene Therapeutics is set to begin trading on the Nasdaq Stock Exchange under the ticker symbol “ALLO.” The stock is expected to debut Thursday, Oct. 11, although an official IPO date has not yet been ...